102 related articles for article (PubMed ID: 12430883)
21. The fall and rise of cost sharing in Kenya: the impact of phased implementation.
Collins D; Quick JD; Musau SN; Kraushaar K; Hussein IM
Health Policy Plan; 1996 Mar; 11(1):52-63. PubMed ID: 10155878
[TBL] [Abstract][Full Text] [Related]
22. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
Stäbler W; Wagner B
Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
[TBL] [Abstract][Full Text] [Related]
23. Modelling the cost effectiveness of antidepressant treatment in primary care.
Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
[TBL] [Abstract][Full Text] [Related]
24. Costs and consequences of stem cell transplantation in children.
Barr RD
Pediatr Transplant; 2003; 7 Suppl 3():7-11. PubMed ID: 12603687
[TBL] [Abstract][Full Text] [Related]
25. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
26. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
28. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
29. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group.
Ramsey SD; Patrick DL; Albert RK; Larson EB; Wood DE; Raghu G
Chest; 1995 Dec; 108(6):1594-601. PubMed ID: 7497767
[TBL] [Abstract][Full Text] [Related]
31. Guidelines for rapid estimation of the direct and indirect costs of HIV infection in a developing country.
Over M; Bertozzi S; Chin J
Health Policy; 1989; 11(2):169-86. PubMed ID: 10292983
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
33. [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation].
Groot MT; van Agthoven M; Löwenberg B; Willemze R; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2004 Mar; 148(10):480-4. PubMed ID: 15042895
[TBL] [Abstract][Full Text] [Related]
34. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
35. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma.
Jerjis S; Croockewit S; Preijers F; Schaap N; De Witte T
Leuk Lymphoma; 2000 May; 37(5-6):551-60. PubMed ID: 11042515
[TBL] [Abstract][Full Text] [Related]
36. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
37. Costs of allogeneic hematopoietic stem cell transplantation.
Svahn BM; Alvin O; Ringdén O; Gardulf A; Remberger M
Transplantation; 2006 Jul; 82(2):147-53. PubMed ID: 16858272
[TBL] [Abstract][Full Text] [Related]
38. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of decentralised care model for managing MDR-TB in India.
John D; Chatterjee P; Murthy S; Bhat R; Musa BM
Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
